Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
5 hedge funds and large institutions have $54K invested in Biostar Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
69% more capital invested
Capital invested by funds: $32K → $54K (+$22K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$25.2K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$16K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| $28K | +$11.8K | +6,669 | +75% |
|
|
VF
2
Virtu Financial
New York
| $25K | +$25.2K | +14,186 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $1K | -$5.9K | -3,320 | -91% |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$16K | -12,482 | Closed |
|
BSPM Hedge Fund Activity: Q4 2017 in Review
5 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q4 2017, worth a combined $54K — up 69% from $32K a quarter earlier.
Fund positioning in BSPM was balanced in Q4 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $25.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $16K sold.
- 5 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $54K of Biostar Pharmaceuticals, Inc. stock for Q4 2017, up 69% quarter-over-quarter.
- 1 fund opened new Biostar Pharmaceuticals, Inc. positions in Q4 2017 and 1 closed out, a net change of 0 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q4 2017 was Virtu Financial, an estimated $25.2K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q4 2017 was Citadel Advisors, an estimated $16K sold.
Based on aggregated 13F filings for Q4 2017.